Experts and Patients write about drugs
Moderate to severe pain in cancer and severe pain in other diseases, unresponsive to non-opioid analgesics. The product is not suitable for the treatment of acute pain. [/DrWidg_Content]
The preparation is indicated to reduce the duration of neutropenia and reduce the incidence of febrile neutropenia in patients receiving chemotherapy with cytotoxic drugs for an established malignant tumor (except chronic myeloid leukemia and myelodysplastic syndromes) and to reduce the duration of neutropenia in patients undergoing myeloablative therapy prior to bone marrow transplantation, who are at increased risk of prolonged severe neutropenia. The safety and efficacy of the medicinal product are similar in adults and children receiving chemotherapy with cytotoxic drugs. The preparation is indicated for the mobilization of peripheral blood progenitor cells (ang. PBPC). In children or adult patients with severe congenital, cyclic or idiopathic neutropenia with absolute neutrophil count (ANC) ≤0,5 x 109 / l and a history of severe or recurrent infections, Long-term administration is indicated to increase neutrophil counts and reduce the frequency and duration of symptoms associated with infection. The preparation is indicated in the treatment of chronic neutropenia (ANC ≤1,0 x 109l) in patients with advanced HIV infection, to reduce the risk of bacterial infections, when other treatments for neutropenia cannot be used. [/DrWidg_Content]